Navigation Links
GenVec to Present at the 2011 10th Annual BIO Investor Forum
Date:10/18/2011

GAITHERSBURG, Md., Oct. 18, 2011 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a Company overview highlighting recent developments at the 2011 10th Annual BIO Investor Forum on Tuesday, October 25, 2011 at 3:00 p.m. PDT at the Palace Hotel in San Francisco.

A webcast of Dr. Fischer's presentation will be available both live and on replay. The presentation will be available via webcast at http://www.veracast.com/webcasts/bio/investorforum2011/14112492.cfm. A replay will also be available for 90 days following the live presentation. The live webcast and subsequent archived replay of GenVec's presentation may also be accessed via the investors and media section of the Company's Web site at http://ir.genvec.com under "Events & Presentations."

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission. Retail Investor and Media Contact:Institutional Investor Contact:GenVec, Inc.

S.A. Noonan CommunicationsDouglas J. Swirsky

Susan A. Noonan(240) 632-5510(212) 966-3650dswirsky@genvec.com

susan@sanoonan.com
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GenVec Renews Stockholder Rights Plan
2. GenVec Reports First Quarter 2011 Financial Results
3. GenVec Regains Compliance with NASDAQ Listing Requirements
4. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
5. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
6. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
7. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
8. GenVec Reports Third Quarter 2009 Financial Results
9. GenVec Announces Third Quarter 2009 Results Conference Call
10. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
11. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Franz Inc ., the leading supplier ... has been named a ‘Champion’ by Bloor Research in its recent Graph Database ... its class, and, thanks to Gruff, it was rated as the easiest product to ...
(Date:3/28/2017)... Summary This report provides all ... its partnering interests and activities since 2010. Description The ... insight into the partnering activity of one of the world,s ... are prepared upon purchase to ensure inclusion of the most ... report will be delivered in PDF format within 1 working ...
(Date:3/28/2017)... , March 28, 2017  Viking Therapeutics, Inc. ... the development of novel therapies for metabolic and endocrine ... Brian Lian , Ph.D., will deliver a corporate presentation ... NASH Investor Conference, being held April 3, 2017 at ... Details for this presentation are as follows: ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... effects and diminished effectiveness over time. A recent study published in STEM CELLS ... by stimulating subventricular zone (SVZ) stem cells to produce more neural cells. ...
Breaking Biology Technology:
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and ... 2022", published by MarketsandMarkets, the market is expected to be worth USD 18.98 ... Continue Reading ... ...      ...
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
Breaking Biology News(10 mins):